Proventis Partners. FOR WHAT TRULY COUNTS



M&A Facts Quarterly Q3 – 2023Specialty Chemicals & Materials Sector



Specialty Chemicals & Materials - M&A-Highlights and Market Insights

Data source: S&P Capital IQ. Analysis by Proventis Partners.

- ► Trading and transaction multiples Compared to Q2 2023, trading multiples decreased slightly, with an EBITDA median of 10.8x. Likewise, Transaction multiples decreased from 16.1x in Q2 to 10.5x EV/EBITDA in Q3 2023.
- ▶ Review and outlook In the last 3 months the overall outlook did not change. Decreasing earnings in nearly all areas of the Chemical Industry did raise the uncertainty of the future development which had an impact on the duration and the number of transaction processes. In Q3 transactions reached the lowest level in the last 2 years. Examples –amongst others- are the sale of Merck's Surface Solutions or CMO producer ESIM which last longer than expected. Nonetheless, there are several interesting targets especially in the food and cosmetics segment which are expected to be sold within the coming 6 months, e.g. IFFs Lucas Meyer cosmetics business, BASF food and cosmetic business at the Illertissen site in Germany as well as Corbion's Food emulsifier business. Others like
- Evonik's Superabsorbent Materials business or HIG Capital's Fluids producer Recochem are expected to be sold in Q4.
- ▶ Notable transactions The industry saw several interesting deals in Q3 with KKR boosting its chemicals portfolio with 1.3 USDbn deal for Chase Corporation, a specialty chemicals firm focused on protective materials for high-reliability applications; DuPont largely completing its planned exist of the former Mobility & Materials segment with the 80.1% sale of the Delrin® Business to financial sponsor TJC, valuing the business at 1.8 USDbn; and Eastman Chemical Co.'s divestment of its Texas City Operations to INEOS Acetyls, a leading global producer and supplier of acetic acid and related chemicals for 490 USDm. HIG Capital sold Specialty Solvents and -fuels producer to ICIG and the Univar Distributor sale to Apollo (8.1 USDbn) was closed. After a short holding period EQT sold hygiene chemicals producer Schülke to a consortium led by Athos, the Strüngmann family office.

Specialty Chemicals & Materials Peer Group


Note: TEV = Total Enterprise Value. LTM = Last Twelve Months. Data source: S&P Capital IQ. In €m.

Company Name	Country	Market Cap	TEV	Total Revenue LTM	EBITDA LTM ¹⁾	TEV/EBITDA LTM Q2 2023 ²⁾ L		Q3 vs. Q2 Trend
Merck KGaA	Germany	68'760	78'089	22'061	6'227	11.4x	12.2x	Δ
Bayer Aktiengesellschaft	Germany	44'651	83'714	48'714	11'135	7.3x	7.4x	Δ
Sika AG	Switzerland	37'087	44'765	10'837	1'897	22.2x	22.3x	Δ
Lonza Group AG	Switzerland	32'662	33'515	6'468	1'907	20.6x	17.1x	∇
DuPont de Nemours, Inc.	United States	32'351	36'267	11'480	2'773	11.2x	11.9x	Δ
Henkel AG & Co. KGaA	Germany	26'486	28'302	22'410	2'731	11.7x	9.8x	∇
DSM-Firmenich AG	Switzerland	21'289	23'331	8'745	583	20.4x	36.4x	Δ
Akzo Nobel N.V.	Netherlands	11'682	16'260	10'866	1'026	16.2x	14.3x	∇
Yara International ASA	Norway	9'146	12'821	16'405	1'772	3.2x	5.3x	Δ
Evonik Industries AG	Germany	8'073	11'984	17'109	1'779	5.2x	6.2x	Δ
Axalta Coating Systems Ltd.	United States	5'635	8'558	4'629	738	12.7x	10.8x	∇
Clariant AG	Switzerland	4'929	6'050	5'035	739	5.7x	7.2x	Δ
LANXESS Aktiengesellschaft	Germany	2'077	4'957	7'835	636	7.4x	8.0x	Δ
Median						11.4x	10.8x	∇

- 1) EBITDA LTM does not include income (loss) from affiliates.
- Multiples are calculated based on last reported LTM EBITDA including income (loss) from affiliates.

Specialty Chemicals & Materials Peer Group Trading Multiples

Data source: S&P Capital IQ.




Recent Specialty Chemicals & Materials M&A Transactions

Note: EV = Total Enterprise Value. Total Transaction Value in €m. Data source: S&P Capital IQ. Selection of transactions by Proventis Partners

Announced Date	Target	Target Country	Acquirer	Acquirer Country	Acquired Stake %	Total Trans- action Value	Implied EV/ EBITDA
28/09/2023	Texas City Operations of Eastman Chemical Company	US	INEOS Acetyls Americas Limited	UK	100	464	n/a
21/09/2023	BMP s.r.l.	IT	Essentra plc	UK	100	37	n/a
01/09/2023	Seiko PMC Corporation	JP	The Carlyle Group Inc.	US	45	94	11.10
29/08/2023	VIACOR Polymer GmbH	DE	Sto SE & Co. KGaA	DE	50	n/a	n/a
21/08/2023	Delrin® acetal homopolymer (H-POM) business of DuPont de Nemours, Inc.	NL	TJC LP	US	80	1'470	n/a
21/08/2023	CannaCare Health GmbH	DE	SynBiotic SE	DE	100	n/a	n/a
17/08/2023	T&K Toka Co., Ltd.	JP	Bain Capital Private Equity, LP	US	100	238	10.26
07/08/2023	Chem Masters Del Peru SA.	PE	Sika AG	СН	100	n/a	n/a
28/07/2023	Qualicaps Co., Ltd.	JP	Roquette Frères S.A.	FR	100	n/a	n/a
21/07/2023	Chase Corporation	US	Kohlberg Kravis Roberts & Co.	US	100	1'235	13.58
20/07/2023	CRAFT 1861 Global Holdings Inc.	CA	Nano Cures Inc.	US	100	2'272	n/a
12/07/2023	Gleitsmann Security Inks GmbH	DE	IN Groupe	FR	100	n/a	n/a
08/07/2023	F.I.S Fabbrica Italiana Sintetici S.p.A.	IT	Bain Capital Private Equity, LP; Nine Trees Group S.p.A.	US/IT	100	n/a	n/a
03/07/2023	Bayer's phytosanitary products factory in Valencia	ES	Industrias Químicas del Valles S.A.	ES	100	n/a	n/a
03/07/2023	Novachem Srl	AR	Evonik Industries AG	DE	100	n/a	n/a


Specialty Chemicals & Materials M&A Deal Count, Recorded Transaction Volume 2021-2023

Data Source: S&P Capital IQ.



Specialty Chemicals & Materials M&A Transaction Multiples 2021-2023

Implied Transaction Enterprise Value / EBITDA of announced transactions with disclosed multiple. Data Source: S&P Capital IQ.



Specialty Chemicals & Materials Operating Financial Metrics

Q2 23 data only. Q3 23 data not yet released. In €m or % where indicated. Data source: S&P Capital IQ.

Company Size Small Cap Mid Cap Large Cap 1 to 250 251 to 2,500 >2,500 Revenue in €m Revenue in €m Revenue in €m Average Revenue in €m Average Revenue in €m 575 Average Revenue in €m 7 727 78 1.947 Number of companies Number of companies 672 Number of companies 180 **EBIT Margin** (in %) 20 Large Cap 15 - Mid Cap Small Cap 10 5 Q2/2022 Q2/2023 Q3/2021 $\Omega 4/2021$ $\Omega 1/2022$ Q3/2022 04/2022 Q1/2023 Year-on-Year **Revenue Growth** (in %) 30 Large Cap 25 Mid Cap 20 Small Cap 15 10 0 Q3/2021 Q4/2021 Q1/2022 Q2/2022 Q3/2022 Q4/2022 Q1/2023 Q2/2023 **Debt/EBITDA** 2 Large Cap Mid Cap Small Cap Q3/2021 Q4/2021 Q1/2022 Q2/2022 Q3/2022 Q4/2022 Q1/2023 Q2/2023 Market Capitalization/Revenue 3.5 Large Cap 3.0 - Mid Cap 2.5 Small Cap 2.0 15 1.0 0.5

Q4/2021

Q1/2022

Q2/2022

Q3/2022

Q4/2022

Q1/2023

Q3/2021

Q2/2023

M&A Facts Quarterly Q3-23 **Specialty Chemicals & Materials**

Proventis Partners.


Specialty Chemicals & Materials M&A Deal Analysis

Announced transactions. Implied M&A Enterprise Value / LTM EBITDA of announced transactions with disclosed multiple. Data Source: S&P Capital IQ.

Deal count by Target Region 296 **EBITDA Multiple (LTM) by Target Region** Europe 236 223 205 192 Europe 6.0x 189 25% 180 28% 165 26% United States and Canada 8.9x 32% United States and Canada 42% 31% 26% 41% 34% 33% 31% Asia / Pacific 14 6x 33% 29% 31% Asia / Pacific Rest of World 39% 33% 28% 32% 38% 31% Rest of World \ Ω1 Ω2 Ω 3 Q4 Ω1 Q2 Q3 2021 2022 2023

Deal count by Investor Type

Announced transaction with identified investors.




EBITDA Multiple (LTM) by Investor Type



Deal count by Company Size

Announced transactions with disclosed annual pre-transaction revenues.



EBITDA Multiple (LTM) by Company Size



Notes

The analysis considers announced transactions only. Recent Transactions and Quarterly Multiples only include transactions with available Enterprise Values (EV). As Capital IQ constantly updates its database, the values might differ from previous M&A Facts.

This document is intended to provide our clients selected information on the Specialty Chemicals & Materials industry. The material presented is based on sources we consider as reliable. Proventis Partners makes no representation as to the completeness or reliability of the information shown herein. Our "M&A Facts" publication is intended for the private use of our clients for information purposes only and the information presented does not represent any offer or commercial recommendation. This document may be copied or redistributed without the knowledge and consent of Proventis Partners. Proventis Partners is a trademark of Proventis Partners Holding GmbH, Munich, Germany.

Dusseldorf, Germany

Proventis Partners GmbH Harald Poeschke, Partner h.poeschke@proventis.com T: +49 211 540 10 801

Hamburg, Germany

Proventis Partners GmbH Jost Hartmann, Partner j.hartmann@proventis.com T: +49 40 360 9759-0

Munich, Germany

Proventis Partners GmbH Jan Poerschmann, Partner j.poerschmann@proventis.com T: +49 89 388 88 1-0

Zurich, Switzerland

Proventis Partners AG Christoph Studinka, Partner c.studinka@proventis.com T: +41 44 536 3630



Proventis Partners is exclusive Member of Mergers Alliance in German-speaking Europe.

Contact - M&A Facts Specialty Chemicals & Materials Dr. Uwe Nickel

u.nickel@proventis.com T: +41 44 536 3630